Preliminary Study on the Development and Reliability and Validity of Attention Rating Scale

NCT ID: NCT06207279

Last Updated: 2024-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

240 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-28

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study, based on preliminary experimental results, literature review, and expert consultations, developed the Attentional Rating Scale (ARS). The aim was to rapidly assess participants' attention and potential influencing factors. The research focused on the scale's reliability and validity among healthy adults. Additionally, the Attention Network Test (ANT) served as the gold standard for evaluating attention. The study attempted to identify correlations between various dimensions of attention and the three attentional networks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. To adiministrate 60 healthy subjects to evaluate internal consistency reliability.
2. To choose 20 cases for ARS retesting 7 days after the first ARS evaluation.
3. To evaluate the split half reliability through the Spearman Brown coefficient.
4. To apply principal component analysis for structural validity analysis.
5. Using the Attention Network Test (ANT) and Toronto Hospital Alertness Test (THE) as gold standards, the Pearson correlation coefficient was used for criterion validity analysis.
6. To administrate 60 patients with MDD, ADHD and insomnia disorder testing the discrimination validity of ARS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Insomnia Attention Disturbances Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Major Depressive Disorder

Patients meeting the diagnostic criteria for Major Depressive Disorder (MDD) according to DSM-5.

rating

Intervention Type DIAGNOSTIC_TEST

rating scales, test ANT

Chronic Insomnia Disorder

Patients meeting the diagnostic criteria for Chronic Insomnia Disorder according to ICSD-3.

rating

Intervention Type DIAGNOSTIC_TEST

rating scales, test ANT

Health Control

Healthy population.

rating

Intervention Type DIAGNOSTIC_TEST

rating scales, test ANT

Attention Deficit and hyperactivity Disorder

Patients meeting the diagnostic criteria for Attention Deficit and hyperactivity Disorder (ADHD) according to DSM-5.

rating

Intervention Type DIAGNOSTIC_TEST

rating scales, test ANT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rating

rating scales, test ANT

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Major Depressive Disorder (MDD) or attention deficit hyperactivity disorder (ADHD) diagnosed according to DSM-5, or Chronic Insomnia Disorder diagnosed according to ICSD-3
2. Ages between 18 and 60 years old
3. Right-handed
4. Educational level ≥5 years or IQ ≥90, capable of understanding and reading Chinese.

Exclusion Criteria

1. Currently diagnosed with any other DSM-5 mental disorders (according to MINI 7.0) or ICSD-3 sleep-wake disorders, apart from MDD, ADHD or insomnia disorder
2. Currently and past history of neurological disorders and physical illnesses with subjectives
3. Consumed alcohol in the week preceding the enrollment
4. Using antidepressants, antipsychotics, mood stabilizers, or other central nervous system-acting drugs for at least 4 weeks in the current episode
5. Undergoing any physical treatments such as ECT, neuromodulation therapy or Traditional Chinese Medicine treatment in the past 6 months
6. Refused to sign the informed consent form
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking University Sixth Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xueqin Wang

Principle Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xueqin Wang, doctor

Role: PRINCIPAL_INVESTIGATOR

Peking University Sixth Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking University Sixth Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xinyang Zhang, master

Role: CONTACT

+8610-62723770

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xueqin Wang, MD

Role: primary

+8610-82077885

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-056

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.